17th JPIAMR transnational call for research projects - AMR Interventions 2024 (IMPACT)

General Information

• Type: Partner looking for project
• Organisation: Karolinska Institutet
• Country: Sweden (SE)
• Career stage: Other.

Research area

• Scientific area(s) of the call:
  1. Topic 2: Improve and/or, compare and/or evaluate strategies, technologies, treatments, methods, protocols or data collection based on existing interventions, aiming to prevent or reduce the emergence or spread of antibacterial or antifungal resistance or to treat/cure infections caused by resistant bacteria/fungi and recommend new policies.
• Subtopics:
  1. Improve and/or compare and/ or evaluate the effectiveness of existing interventions (e.g. cost effectiveness clinical utility, socio-economic adaptability, reducing AMR emergence, spread, transmission, treatment etc.)
  2. Identify the barriers to uptake, including factors leading to the success or failure of previously run pilot interventions, and when applicable design solutions to overcome them.

• One Health Setting:

  Human Health

• Keywords:

  ebselen;silver;thioredoxin;ebsargent;cross-resistance

• Brief description of your expertise / expertise you are looking for:

  We have developed, patented and further studied the combination of silver and ebselen in the form of EbsArgent, which efficiently kills both Gram positive and Gram negative bacteria (bactericidal effect) without over toxicity to human or mammalian cells, and excellent results in mouse models. No cross-resistance with other antibiotics is seen. See www.txnsystems.com for details. Our expertise lies in biochemistry, microbiology and mammalian model systems, with a focus on redox biology including the thioredoxin and glutathione systems.

• Brief description of your project / the project you would like to join:

  Within JPIAMR we wish to further evaluate EbsArgent in diverse infection models, evaluate optimal formulation approaches for Human Phase I trials, and bench-mark towards other antibiotics. We also wish to study further the molecular mechanisms of action of EbsArgent together with partners having complementary expertise. We have a strong academic team (see https://ki.se/en/mbb/elias-arner-research-group) as well as our spin-off company for antibiotic development (www.txnsystems.com) through which we are happy to team up in productive and synergistic consortia together with partners having complementary expertise but a joint interest with us in redox biology and AMR projects.

Elias Arnér

• Organisation: Karolinska Institutet
• Position: Professor
• E-mail: elias.arner@ki.se
• Phone: 0046852486983
• Web: ki.se/en/mbb/elias-arner-research-group